ProQR Therapeutics NV expected to post a loss of 8 cents a share - Earnings Preview

ProQR Therapeutics NV

01/08/2025 14:31

ProQR Therapeutics NV PRQR.OQ PRQR.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2025

The Leiden Zuid-holland-based  company is expected to report a 29.4% decrease in revenue to €4.452 million from €6.31 million a year ago, according to the mean estimate from 7 analysts, based on LSEG data.

​LSEG's mean analyst estimate for ProQR Therapeutics NV is for a loss of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for ProQR Therapeutics NV is $9.00, about 76.7% above its last closing price of $2.10

Previous quarterly performance (using preferred earnings measure in euros). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.11
-0.09
-0.10
Missed
-8.1
Dec. 31 2025
-0.11
-0.09
-0.09
Met
-1.7
Sep. 30 2024
-0.10
-0.11
-0.10
Beat
5.2​
Jun. 30 2024
-0.11
-0.12
-0.03
Beat
75.9
​​Mar. 31 2024
-0.12
-0.11
-0.09
Beat
17.8
Dec. 31 2023
-0.10
0.01
-0.07
Missed
-745.2​
Sep. 30 2023
-0.10
-0.09
-0.07
Beat
17.8
Jun. 30 2023
-0.11
-0.11
-0.10
Beat
10

This summary was machine generated August 1 at 13:31 GMT.  All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)